(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Pick Your Favored method of transportation - 2A definitive Bike Standoff: Decision in favor of Your Number one Ride
- 3Vote in favor of Your #1 BWM Vehicles
- 4Yoshi mania, Happy Meals and not-so-great reviews: A small talk guide to 'The Super Mario Galaxy Movie'
- 5Nestlé recalls infant formula in 49 countries. See list.
- Architect Frank Gehry has died: See his most iconic buildings
- Novo and Lilly cut prices of weight-loss drugs in China
- Reclassifying Achievement: Individual Accounts of Seeking after Interests
- UN warns civil liberties under threat due to war in Middle East
- CDC studies show value of nationwide wastewater disease surveillance, as potential funding cut looms
- Climate change is straining Alaska's Arctic. A new mining road may push the region past the brink
- Exemplary Fragrances: A Manual for Notorious Scents
- What's inside Mexico's Popocatépetl? Scientists obtain first 3D images of the whole volcano
- Toyota’s Next Big Sports Car Might Apparently Be a Turbocharged All-Paw Beast
